share_log

Virax Biolabs | 6-K: Report of foreign private issuer (related to financial reporting)

Virax Biolabs | 6-K: Report of foreign private issuer (related to financial reporting)

Virax Biolabs | 6-K:外国发行人报告(业绩相关)
美股SEC公告 ·  2024/10/31 20:11

Moomoo AI 已提取核心信息

Virax Biolabs Group Limited has scheduled its 2024 Annual General Meeting for December 12, 2024. Shareholders will vote on four key proposals: ratifying Reliant CPAs PC as auditor, re-electing five current directors, approving the 2024 Equity Incentive Plan, and authorizing potential meeting adjournment.The company seeks to re-elect James Foster, Nigel McCracken, Yair Erez, Evan Norton, and Nelson Haight as directors. The proposed 2024 Equity Incentive Plan would reserve 250,000 ordinary shares for issuance, allowing for various equity awards to attract and retain key personnel.Shareholders of record as of October 14, 2024, are eligible to vote. The meeting will be held at BioCity Glasgow, with options for in-person attendance and proxy voting. The Board recommends voting 'FOR' all proposals.
Virax Biolabs Group Limited has scheduled its 2024 Annual General Meeting for December 12, 2024. Shareholders will vote on four key proposals: ratifying Reliant CPAs PC as auditor, re-electing five current directors, approving the 2024 Equity Incentive Plan, and authorizing potential meeting adjournment.The company seeks to re-elect James Foster, Nigel McCracken, Yair Erez, Evan Norton, and Nelson Haight as directors. The proposed 2024 Equity Incentive Plan would reserve 250,000 ordinary shares for issuance, allowing for various equity awards to attract and retain key personnel.Shareholders of record as of October 14, 2024, are eligible to vote. The meeting will be held at BioCity Glasgow, with options for in-person attendance and proxy voting. The Board recommends voting 'FOR' all proposals.
Virax Biolabs Group Limited已将其2024年年度股东大会定于2024年12月12日召开。股东将对四项关键提议进行投票:批准Reliant CPAs PC为审计师,连任五位现任董事,批准2024年股权激励计划,以及授权潜在会议休会。公司希望连任James Foster、Nigel McCracken、Yair Erez、Evan Norton和Nelson Haight为董事。提议的2024年股权激励计划将保留250,000股普通股用于发行,为吸引和留住关键人员提供多种股权奖励。截至2024年10月14日的股东记录有资格投票。会议将在BioCity Glasgow举行,提供现场出席和代理投票的选项。董事会建议对所有提案投“支持”。
Virax Biolabs Group Limited已将其2024年年度股东大会定于2024年12月12日召开。股东将对四项关键提议进行投票:批准Reliant CPAs PC为审计师,连任五位现任董事,批准2024年股权激励计划,以及授权潜在会议休会。公司希望连任James Foster、Nigel McCracken、Yair Erez、Evan Norton和Nelson Haight为董事。提议的2024年股权激励计划将保留250,000股普通股用于发行,为吸引和留住关键人员提供多种股权奖励。截至2024年10月14日的股东记录有资格投票。会议将在BioCity Glasgow举行,提供现场出席和代理投票的选项。董事会建议对所有提案投“支持”。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息